Personalis, Inc. (PSNL)
Automate Your Wheel Strategy on PSNL
With Tiblio's Option Bot, you can configure your own wheel strategy including PSNL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PSNL
- Rev/Share 0.9798
- Book/Share 2.3706
- PB 1.9362
- Debt/Equity 0.2142
- CurrentRatio 6.9056
- ROIC -0.2645
- MktCap 405412209.0
- FreeCF/Share -0.534
- PFCF -8.6797
- PE -4.7755
- Debt/Assets 0.1625
- DivYield 0
- ROE -0.4878
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PSNL | Guggenheim | -- | Buy | -- | $6 | May 15, 2025 |
| Initiation | PSNL | Craig Hallum | -- | Buy | -- | $8 | March 17, 2025 |
News
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection. “These studies continue to expand the clinical data for NeXT Personal into new areas, in.
Read More
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Personalis, Inc. (NASDAQ:PSNL ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital William Bonello - Craig-Hallum Vidyun Bais - BTIG Daniel Brennan - Cowen Yuko Oku - Morgan Stanley Swayampakula Ramakanth - H.C. Wainwright Operator Greetings.
Read More
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Personalis (PSNL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.26 per share a year ago.
Read More
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
Published: April 22, 2025 by: Business Wire
Sentiment: Neutral
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois. “Our collaborators are excited to present new data, including.
Read More
Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Personalis, Inc. (NASDAQ:PSNL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and welcome to the Personalis Fourth Quarter 2024 Earnings Conference Call.
Read More
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Read More
About Personalis, Inc. (PSNL)
- IPO Date 2019-06-20
- Website https://www.personalis.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Christopher M. Hall
- Employees 228